HLA-DR expression in melanoma: from misleading therapeutic target to potential immunotherapy biomarker
Karim Amrane, Coline Le Meur, Benjamin Besse, Patrice Hemon, Pierre Le Noac’h, Olivier Pradier, Christian Berthou, Ronan Abgral, Arnaud Uguen · 2024
Read HLA-DR expression in melanoma: from misleading therapeutic target to potential immunotherapy biomarker by Karim Amrane, Coline Le Meur, Benjamin Besse, Patrice Hemon, Pierre Le Noac’h, Olivier Pradier, Christian Berthou, Ronan Abgral, Arnaud Uguen (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10827890.txt.
Description
Karim Amrane and a team of expert co-authors present a review of a cell marker, HLA-DR, in melanoma skin cancer. Immune drugs have transformed care for this cancer, yet about half of patients gain little or relapse. HLA-DR is a display protein that shows up oddly on melanoma cells.
Once floated as a drug target, it now looks more useful as a signpost. The review gathers what is known on whether its presence predicts who will answer immune therapy. The expert group weighs the evidence across studies and notes the gaps. Finding such markers could help match patients to treatment sooner. The authors set out what trials should test next.
Catalog record
| CREATOR | Karim Amrane, Coline Le Meur, Benjamin Besse, Patrice Hemon, Pierre Le Noac’h, Olivier Pradier, Christian Berthou, Ronan Abgral, Arnaud Uguen |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 28 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |